• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Percentage of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Dictionary: Timely review of regulatory cases that come from the field is important as it allows FDA to take appropriate regulatory action such as issuance of a warning letter to the regulated industry. This can lead to a timely correction of problems in the industry resulting in a safer food supply.

Information is current as of September 30, 2014.

Fiscal Year - 2013

Skip graphic and jump to text data

TimeTargetPercentage
Oct 20128067
Nov 20128087
Dec 20128089
Jan 20138081
Feb 20138080
Mar 20138088
Apr 20138067
May 20138096
Jun 20138092
Jul 20138065
Aug 20138091
Sep 20138076

FY 2013 Overall: 83%

Total number of regulatory cases referred to OFS that were reviewed within the timeframe given to OFS in the Case Management System (measures time in OFS only) in the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2012N/A18
Nov 2012N/A34
Dec 2012N/A31
Jan 2013N/A21
Feb 2013N/A8
Mar 2013N/A22
Apr 2013N/A16
May 2013N/A24
Jun 2013N/A24
Jul 2013N/A13
Aug 2013N/A43
Sep 2013N/A19

FY 2013 Total: 270

Total number of regulatory cases referred to OFS in the month that are due within the month

Fiscal Year - 2013
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2012N/A27
Nov 2012N/A39
Dec 2012N/A35
Jan 2013N/A26
Feb 2013N/A10
Mar 2013N/A25
Apr 2013N/A24
May 2013N/A25
Jun 2013N/A26
Jul 2013N/A20
Aug 2013N/A47
Sep 2013N/A21

FY 2013 Total: 325

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.